Taurolidine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Taurolidine
- Taurolidine: From Catheter-Related Bloodstream Infection Prevention to Diabetic Cataract
Taurolidine: From Catheter-Related Bloodstream Infection Prevention to Diabetic Cataract
One-Sentence Summary
Taurolidine is a taurine derivative internationally used as a catheter lock solution for the prevention of catheter-related bloodstream infections, with secondary use as an adjunct in peritoneal malignancy. The TxGNN model predicts it may be effective for Diabetic Cataract, but this prediction is currently supported by no clinical trials and no published literature — it is a pure knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally licensed in the UK; internationally used as a catheter lock solution for prevention of catheter-related bloodstream infections, and as adjunct therapy in peritoneal malignancy |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.94% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for taurolidine is not currently available in this Evidence Pack (flagged as a data gap). Based on the available rationale, taurolidine is a taurine derivative — structurally two taurine molecules bridged by a methylol group — with two known pharmacological actions: an antibacterial effect (disruption of bacterial cell walls and inactivation of endotoxins) and an antitumour effect (induction of apoptosis, anti-angiogenesis). It is primarily used as a catheter lock solution for prevention of catheter-related bloodstream infections, with a secondary role as adjunct therapy in peritoneal malignancy.
Taurine itself plays a recognised role in lens and retinal metabolism, and taurine deficiency has been associated with cataract formation in animal models. This is the conceptual basis for the TxGNN link between taurolidine and diabetic cataract. However, taurolidine’s active mechanism — cytotoxicity via its methylol group and its antimicrobial/antitumour activity — has no established direct connection to lens protein glycation or oxidative stress, which are the principal pathological mechanisms of diabetic cataract. The link is therefore an indirect, structure-based inference from the knowledge graph rather than a pharmacologically grounded hypothesis.
It is worth noting that among the top TxGNN-predicted indications for taurolidine, diabetic retinopathy (rank 9, score 98.86%) has a somewhat stronger conceptual rationale, as taurolidine’s anti-angiogenic properties overlap theoretically with the pathological neovascularisation seen in diabetic retinopathy. Even so, there are no preclinical ophthalmic pharmacology data, no information on aqueous/vitreous penetration, and no in vitro or in vivo studies confirming this — so this remains a mechanistic hypothesis only, for both indications reviewed here.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
UK Market Information
Taurolidine currently holds no UK marketing authorisation and is not marketed in the United Kingdom. No product licences, brand names, or approved indication texts are available for this drug in the UK regulatory dataset.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5 (model-prediction-only) candidate with no supporting clinical trials or literature, no established mechanistic link to diabetic cataract pathology, and taurolidine currently has no UK marketing authorisation. Key safety data (warnings, contraindications) are also unavailable, which blocks even a preliminary safety assessment.
To proceed, the following is needed:
- SmPC/product labelling data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action data from DrugBank or primary literature
- Preclinical ophthalmic pharmacology and lens/aqueous humour penetration data
- Any in vitro/in vivo evidence specifically linking taurolidine to diabetic cataract or diabetic retinopathy pathology
- Assessment of a viable route of administration for an ophthalmic indication, given taurolidine’s current systemic/intracavitary use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.